BCG in the immunotherapy of non-Hodgkin's malignant lymphomas: preliminary results of a controlled trial.
Thirty-three patients exhibiting non-Hodgkin's malignant lymphoma with one or more criteria of poor prognosis and in whom complete remission had been induced by an association of chemo + radio + chemotherapy were randomized to either receive BCG or no further treatment. The present results indicate that BCG may be useful to maintain remission in about one-third of the patients, but these results are not yet significant.
D000970:Antineoplastic Agents / Q000008:administration & dosage; D001500:BCG Vaccine / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D008223:Lymphoma / Q000628:therapy*; D008875:Middle Aged; D012075:Remission, Spontaneous
D000970:Antineoplastic Agents; D001500:BCG Vaccine